GIOTRIF® :
The 1st choice in 1st-line
Superior efficacy vs gefitinib and vs chemotherapy
demonstrated in 3 large trials in 1st-line EGFR M+ NSCLC1-4*
demonstrated in 3 large trials in 1st-line EGFR M+ NSCLC1-4*
GIOTRIF® safety and effectiveness in the real world
Document ID: PC-MY-102094
13/01/2022
Author: Boehringer Ingelheim
123,000
Views
100k 340
RELATED CONTENT
PC-MY-102094
Production date: January 2022
Production date: January 2022